UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/568,409	09/26/2006	Atanas Iliev Lalev	13993-4	7611
1059 BERESKIN AN	7590 04/02/200 ND PARR	EXAMINER		
40 KING STRE		LUM, LEON YUN BON		
BOX 401 TORONTO, OI	N M5H 3Y2		ART UNIT	PAPER NUMBER
CANADA	CANADA			
			MAIL DATE	DELIVERY MODE
			04/02/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/568,409	LALEV ET AL.
Office Action Summary	Examiner	Art Unit
	Leon Y. Lum	1641
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the o	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tinwill apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
1) ■ Responsive to communication(s) filed on 14 F 2a) ■ This action is FINAL. 2b) ■ This 3) ■ Since this application is in condition for alloware closed in accordance with the practice under B	s action is non-final. nce except for formal matters, pro	
Disposition of Claims		
4) ☐ Claim(s) 1-26 and 29-52 is/are pending in the 4a) Of the above claim(s) is/are withdra 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-26 and 29-52 are subject to restrict	wn from consideration.	
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	cepted or b) objected to by the liderawing(s) be held in abeyance. See tion is required if the drawing(s) is objected.	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) ☐ Acknowledgment is made of a claim for foreign a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority document 2. ☐ Certified copies of the priority document 3. ☐ Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal F 6) Other:	ate

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- A. Group I, claims 1-26, 29-42 and 45-49, drawn to a method of separating a first ligand from a second ligand.
- B. Group II, claims 43 and 44, drawn to a method for identifying proteinprotein association.
- C. Group III, claims 50-52, drawn to a reagent kit.
- 2. The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons.

Groups I and II do not share a common technical feature. Group I is directed to a method that requires separating a first ligand from a second ligand by decreasing the

Art Unit: 1641

electrostatic forces between the ligands. Group II is directed to a method that requires replacing lysine, arginine, aspartate, glutamate and/or hisitine with an uncharged or oppositely charged amino acid. These two methods have no corresponding feature in common. Accordingly, Groups I and II lack unity of invention.

For the same reason, Groups II and III lack unity of invention.

Groups I and III have the following technical features in common: a cellular lysate and a wash buffer capable of maintaining the electrostatic forces between a first and second ligand. However, these features are not special technical features because they are taught in the prior art by Sledziewski *et al.* (US 5,155,027) ("Sledziewski"). Sledziewski describes a cellular lysate in column 7, line 26 and a washing step that maintains binding between an antibody and an antigen in column 17, lines 32-48, especially lines 40-41. Accordingly, Groups I and III lack unity of invention.

3. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

If Group I is elected, the following species must also be elected

- A. Means for decreasing the electrostatic forces (elect one below)
 - 1. lonic (claims 22-26)
 - 2. pH (claim 29)
 - 3. Enzymatic (claims 30-31)
- B. Mutation (elect one below)

Art Unit: 1641

1. The second ligand has a mutation (claim 35)

- 2. The second ligand associates with a protein that has a mutation (claim 36)
- C. Second ligand (elect one below)
 - 1. Enzyme (claim 39)
 - 2. Substrate for an enzyme (claim 40)
 - 3. Enzyme and a substrate for a different enzyme (claims 41-42)
 - 4. Glycoprotein (claim 47)
 - 5. Nucleic Acid (claims 48 and 49)
- 4. Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.
- 5. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Art Unit: 1641

For Group I, the claims are deemed to correspond to the species listed above in the following manner: claims 22-26, 29-31, 35-36, 39-42 and 47-49. The following claims are generic: 1-21, 32-34, 37-38, 45-46 and 49.

- 6. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the species have different structural or funcitonal properties that render them distinct.
- 7. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leon Y. Lum whose telephone number is (571) 272-2872. The examiner can normally be reached on Monday to Friday (8:30 am to 5:00 pm).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mark L. Shibuya can be reached on (571) 272-0806. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Art Unit: 1641

/Nelson Yang/ Primary Examiner, Art Unit 1641